Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single-institutional cohort study - 20/03/24
, Sarah M. Knierim, BS a, Felix Luttermann, MD b, Gisela Metzler, MD b, c, Amir S. Yazdi, MD b, d, Jürgen Bauer, MD b, Maximilian Gassenmaier, MD b, e, Andrea Forschner, MD b, Ulrike Leiter, MD b, Teresa Amaral, MD, PhD b, Claus Garbe, MD b, Thomas K. Eigentler, MD b, f, Stephan Forchhammer, MD b, Lukas Flatz, MD a, bAbstract |
Background |
Histopathologic regression of cutaneous melanoma is considered a favorable prognostic factor, but its significance in clinical practice remains controversial.
Objective |
To investigate the prognostic importance of regression in patients with primary cutaneous melanoma undergoing sentinel lymph node (SLN) biopsy and to assess its significance in patients progressing to an unresectable stage requiring systemic therapy.
Methods |
We retrospectively reviewed patients with newly diagnosed melanoma undergoing SLN biopsy between 2010 and 2015 and available information on histopathologic regression (n = 1179). Survival data and associations of clinical variables with SLN status were assessed.
Results |
Patients with regressive melanoma showed favorable relapse-free (hazard ratio [HR], 0.52; P = .00013), distant metastasis–free (HR, 0.56; P = .0020), and melanoma-specific survival (HR, 0.35; P = .00053). Regression was associated with negative SLN (odds ratio, 0.48; P = .0077). In patients who progressed to an unresectable stage, regression was associated with favorable progression-free survival under immune checkpoint inhibition (HR, 0.43; P = .031) but not under targeted therapy (HR, 1.14; P = .73) or chemotherapy (HR, 3.65; P = .0095).
Limitations |
Retrospective, single-institutional design.
Conclusions |
Regression of cutaneous melanoma is associated with improved prognosis in patients eligible for SLN biopsy as well as in patients with unresectable disease receiving systemic therapy with immune checkpoint inhibitors.
Le texte complet de cet article est disponible en PDF.Key words : chemotherapy, clinical research, cutaneous melanoma, drug response, histopathologic regression, immune checkpoint inhibition, oncology, targeted therapy
Abbreviations used : DMFS, HR, ICI, MSS, PFS, RFS, SLN, SLNB, TT
Plan
| Funding sources: None. |
|
| IRB approval status: Reviewed and approved by University of Tuebingen IRB (reference number 286/2018BO2). |
Vol 90 - N° 4
P. 739-748 - avril 2024 Retour au numéro
Article précédent
- Cutaneous squamous cell carcinoma tumor accrual rates in immunosuppressed patients with autoimmune and inflammatory conditions: A retrospective cohort study
- Emily E. Granger, Morgan Groover, Catherine Harwood, Charlotte M. Proby, Emily Karn, Fadi Murad, Chrysalyne D. Schmults, Emily S. Ruiz
- Tape strips detect molecular alterations and cutaneous biomarkers in skin of patients with hidradenitis suppurativa
- Kristina Navrazhina, Yael Renert-Yuval, Saakshi Khattri, Hassan Hamade, Marguerite Meariman, Elizabeth Andrews, Madeline Kim, Monali NandyMazumdar, Digpal S. Gour, Swaroop Bose, Samuel C. Williams, Sandra Garcet, Joel Correa da Rosa, Alice B. Gottlieb, James G. Krueger, Emma Guttman-Yassky
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?